Immunomedics Provides Corporate Update
IMMUNOMEDICS (IMMU)
Last immunomedics earnings: 2/27 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
immunomedics.com/2017/immunomedics-announces-presentations-investor-event-2017-san-antonio-breast-cancer-symposium
Company Research
Source: GlobeNewswire
Sacituzumab Govitecan Achieves a 29 Percent Objective Response Rate in 35 Patients With Advanced Urothelial Cancer Who Failed Prior Platinum-Based Regimens and Immunotherapy Future Steps Include Discussing Registrational Pathways with the FDA Collaboration with Roche will Combine Sacituzumab Govitecan with Atezolizumab (Tecentriq®) in Patients with Previously-Untreated Metastatic Triple-Negative Breast Cancer (mTNBC) Announcement of Phase 3 Study of Sacituzumab Govitecan in the Curative Setting of Breast Cancer In Conjunction with The German Breast Group Resubmission Timeline of the mTNBC BLA Revised for Late November or Early December MORRIS PLAINS, N.J., Sept. 28, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today presented at the European Society for Medical Oncology (ESMO) Annual Congress interim data from the 100-patient cohort of ci
Show less
Read more
Impact Snapshot
Event Time:
IMMU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMMU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMMU alerts
High impacting IMMUNOMEDICS news events
Weekly update
A roundup of the hottest topics